

1 **Physical activity shapes the intestinal microbiome and**
2 **immunity of healthy mice but has no protective effects**
3 **against colitis in MUC2^{-/-} mice**

4

5 **Authors**

6 Mehrbod Estaki^{1,2}, Douglas W. Morck³, Candice Quin¹, Jason Pither¹, Jacqueline A. Barnett¹,
7 Sandeep K. Gill^{1,4}, Deanna L. Gibson^{1*}

8 1 Department of Biology, The Irving K. Barber School of Arts and Sciences, University of British
9 Columbia, Okanagan campus, Kelowna, British Columbia, Canada

10 2 Department of Pediatrics, University of California San Diego, La Jolla, California

11 3 Department of Biological Sciences, University of Calgary, Calgary, Alberta

12 4 School of Population and Public Health, University of British Columbia, Vancouver, British
13 Columbia, Canada

14

15

16 * Corresponding Author

17 Deanna L. Gibson, deanna.gibson@ubc.ca

18

19 **Abstract**

20
21 The interactions among humans, their environment, and the trillions of microbes residing within
22 the human intestinal tract form a tripartite relationship that is fundamental to the overall health of
23 the host. Disruptions in the delicate balance between the intestinal microbiota and their host
24 immunity are implicated in various chronic diseases including inflammatory bowel disease (IBD).
25 There is no known cure for IBD, therefore, novel therapeutics targeting prevention and
26 symptoms management are of great interest. Recently, physical activity in healthy mice was
27 shown to be protective against chemically-induced colitis, however the benefits of physical
28 activity during or following disease onset is not known. In this study, we examine whether
29 voluntary wheel running is protective against primary disease symptoms in a mucin 2 deficient
30 (*Muc2*^{-/-}) life-long model of murine colitis. We show that 6 weeks of wheel running in healthy
31 C57BL/6 mice leads to distinct changes in fecal bacteriome, increased butyrate production, and
32 modulation in colonic gene expression of various cytokines, suggesting an overall primed anti-
33 inflammatory state. However, these physical activity-derived benefits are not present in *Muc2*^{-/-}
34 mice harboring a dysfunctional mucosal layer from birth, ultimately showing no improvements in
35 clinical signs. We extrapolate from our findings that while physical activity in healthy individuals
36 may be an important preventative measure against IBD, for those with a compromised intestinal
37 mucosa, a commonality in IBD patients, these benefits are lost.

38 Introduction

39 Inflammatory bowel diseases (IBD) encompassing Crohn's disease (CD) and Ulcerative
40 colitis (UC) are idiopathic, relapsing chronic diseases characterized by chronic inflammation of
41 the gastrointestinal tract. While pathology varies between UC and CD, both burden patients with
42 common debilitating clinical symptoms such as diarrhea, rectal bleeding, abdominal pain, and
43 weight loss. The etiology of IBD is not known, however a combination of genetic, immunological,
44 and environmental factors is implicated in its development. Most recently, the contribution of the
45 intestinal microbiota in IBD pathogenesis has risen as an active area of research (1). For
46 example, IBD patients have reduced gut microbial diversity (2) and are more likely to have been
47 exposed to antibiotics in 2-5 years preceding their diagnosis (3). In animal models, mice
48 genetically predisposed to colitis (IL-10^{-/-}) are resistant to disease onset while kept under germ-
49 free conditions, however clinical signs instigate immediately following exposure to microbes (4).

50 With incidence of IBD and its burdens rising globally (5), there is an increasing demand
51 for novel therapeutics. Physical activity (PA) has been proposed as both a primary and an
52 adjunct therapy for prevention and treatment of various chronic diseases due to its well
53 documented ability to ameliorate low-grade systemic inflammation (6). Most recently, IBD has
54 been marked as a potential new candidate (7) to yield benefits from regular PA. Studies of PA in
55 rodents have shown attenuated clinical signs of chemically-induced colitis (8–11) that appear to
56 be dependent on the colitis model and type of PA. These studies, however, only assess the role
57 of PA as a preventive measure leading up to induction of acute colitis via a chemical toxin. As
58 so, the potential benefits of PA succeeding or during disease onset is not known. In this study
59 we aimed to address this knowledge gap by utilizing the mucin 2 knock-out (*Muc2*^{-/-}) mouse
60 model of chronic colitis.

61 The human intestinal tract is continuously exposed to the trillions of microbes residing
62 within the mucosal layer of the lumen. Under homeostatic conditions, these microbes are
63 tolerated by the host as they provide essential functions such as digestion of complex
64 carbohydrates, protection against enteric pathogens, and production of beneficial short-chain
65 fatty acids (SCFA), to name a few. Separating the luminal microbes from intestinal epithelial
66 cells (IEC) is a mucus bilayer largely composed of the highly glycosylated protein MUC2. In the
67 colon, the loosely structured outer mucus layer allows for colonization of microbes in a nutrient-
68 rich environment, while the dense inner layer segregates them from the IEC (12). Inflamed
69 intestinal tissues of UC patients commonly display structural defects or thinning of this mucus
70 layer (13), leading to excessive exposure of microbial antigens to the host cells, prompting a
71 chronic state of inflammation and apoptosis leading to further loss of IEC integrity and thus
72 further exposure and injury. *Muc2*^{-/-} mice or those with missense mutations impairing the release
73 of MUC2, are born with an underlying predisposition to intestinal inflammation that show rapid
74 progression of colitis (14). *Muc2*^{-/-} mice generally display early clinical signs of colitis following
75 weaning (~ 1 month) and microscopic tissue pathology as early as two months of age, indicating
76 a moderate-level colitis, reaching high-severity by 4 months (15).

77 We hypothesized that introduction of *Muc2*^{-/-} mice to voluntary wheel running (VWR)
78 immediately following weaning would reduce the severity and delay the onset of clinical signs of

79 colitis. Having recently shown a significant correlation between aerobic fitness and overall
80 microbial diversity and increased butyrate production (16), we hypothesized further that PA-
81 associated protection would be mediated through changes of the intestinal microbiota and their
82 metabolites.

83

84 **Methods**

85 **Experimental procedure** - To test our primary hypothesis that habitual physical activity can be
86 protective during IBD as a treatment, rather than a preventative therapy as has been previously
87 shown, we chose to utilize *Muc2*^{-/-} mice as a life-long model of murine colitis. In our facility,
88 *Muc2*^{-/-} are underweight at birth and display early signs of colitis that are mild to moderate in
89 severity up to ~ 3 months of age, at which point they accelerate rapidly reaching high severity
90 by 4 months. We therefore designed our experiment to conclude prior to the 3 month time-point
91 under the speculation that higher severity of disease symptoms would preclude the animals
92 from voluntarily running on wheels. Following weaning at 5 weeks of age, animals were
93 randomly assigned to individual cages under one of four groups (n=8 per group): Wild-type
94 (WT) C57BL/6 mice with access to a free running wheel (VWR) or a locked wheel (SED), and
95 *Muc2*^{-/-} mice with access to free wheel (MVWR) or a locked wheel (MSED). We chose wheel
96 running as a model of PA over forced exercise, as mice voluntarily run higher total distances on
97 free wheels than when forced on a treadmill (17). Forced exercise can also cause significant
98 stress in rodents (18) and in fact has been shown to exacerbate colitis severity in C57BL/6 mice
99 (9). A six-week VWR intervention period was selected based on previous reports showing this to
100 be sufficient in eliciting significant protection against chemically-induced models of colitis (19,
101 20). The primary responses of interest during this period were weekly clinical signs of colitis and
102 histopathological disease scores at terminus. Additional responses of interest were changes to
103 intestinal microbial composition and function, immunity, and SCFA production in response to
104 PA. The variables associated with these additional responses are described in detail below. By
105 examining these we aimed to elucidate the mechanisms by which PA recruits protective actions.

106 **Animals** - All procedures involving the care and handling of the mice were approved by the
107 UBC Committee on Animal Care, under the guidelines of the Canadian Council on Animal Care.
108 Four-week-old male wild-type (WT) C57BL/6 mice were purchased from Charles River
109 (Vancouver, CA) and kept under specific pathogen-free conditions. *Muc2*^{-/-} mice, generated also
110 on a C57BL/6 genetic background, were bred in house with the founding colonies kindly
111 donated by Dr. Bruce Vallance from the Child and Family Research Institute (UBC Vancouver).
112 All animals were housed in a temperature-controlled room (22 ± 2°C) on a 12h light/dark cycle
113 with access to acidified water and irradiated food (PicoLab Rodent Diet 20-5053, Quebec, CA)
114 *ad libitum*. Assignment of mice to experimental groups were carried out using a random number
115 generator immediately preceding individual cage allocation.

116 **Voluntary wheel running, and food and water intake** - The running wheels (Columbus
117 Instruments, diameter 10.16 cm, width 5.1 cm) were mounted to the top of the cage lids and

118 were programmed to record the total number of revolutions at 1 hr intervals for the duration of
119 the experiment. Body weights, food consumption, and water intake were measured weekly at
120 approximately the same time during the light cycle. Food weight measurements consisted of
121 subtracting the week's remaining pellets on the cage lids and bottoms from that week's starting
122 weight.

123 **Tissue collection** - For fecal sample collection, mice were kept briefly in isolation in sterile and
124 DNAzap-treated containers until defecation. Collected fecal pellets, which were used for
125 microbiome surveying, were immediately snap-frozen in liquid nitrogen then stored in -80 °C
126 until further analyses. Fecal samples were collected on day 1 immediately following assignment
127 to individual cages, and again on the final experiment day immediately preceding tissue
128 collection. Animals were euthanized by cervical dislocation while under deep isoflurane
129 anesthesia. The cecum was isolated, its content removed, and tissue frozen in liquid nitrogen
130 for further analyses of SCFA composition. Colon tissues were collected as follows: starting from
131 distal end, two consecutive ~1.5 cm sections were collected with the most distal section being
132 fixed in 10% neutral buffered formalin for histopathology and the proximal section was stored in
133 RNAlater (Thermo Fisher Scientific) for use in cytokine gene expression assays. All frozen
134 samples were then stored at -80 °C until further use.

135 **Clinical and Histopathological Scoring** - Disease progression and severity in *Muc2*^{-/-} animals
136 was assessed based on an in-house clinical signs scoring system, and represented by a
137 variable we henceforth call "disease score". Briefly, each animal was graded weekly based on
138 the following: observed behavior from a distance, stool/rectal bleeding, stool consistency, weight
139 loss, and hydration, with each variable being assigned a score of 0-4. Humane endpoint was set
140 as a total cumulative score of ≥12, rectal prolapse, or a weight loss of >20% body weight for 2
141 consecutive days. No animals reached a humane endpoint in this study.

142 For histopathological scoring, colon cross-sections were fixed in 10% neutral-buffered formalin
143 at 4°C overnight, washed 3 times with phosphate buffered saline (PBS, pH 7.4), transferred to
144 70% ethanol and sent for dehydration, paraffin-embedding, sectioning, and hematoxylin and
145 eosin (H&E) staining at Wax-it Histology Services (Vancouver, Canada). Tissue slides were
146 coded throughout the microscopy analyses and investigators scoring histopathology were
147 blinded to the groupings. H&E stained sections were viewed under 200x magnification on an
148 Olympus IX81 microscope and the full image stitched together using MetaMorph® software.
149 Stitched images were imported into ImageJ-version 1.51r (21) for scoring. Disease severity in
150 colonic cross sections from the *Muc2*^{-/-} animals were assessed using a previously described
151 scoring system (22). In brief, a total score was calculated for each mouse using the following
152 criteria

- 153 1. *Edema*, as compared to a healthy WT control: 0=no change; 1=mild (<10%);
154 2=moderate (10-40%); 3=profound (>40%)
- 155 2. *Epithelial hyperplasia*, average height of crypts as a percentage above the height of a
156 healthy control where 0=no change; 1=1–50%; 2=51–100%; 3=>100%

157 3. *Epithelial integrity*, shedding and shape of the epithelial layer as compared to healthy
158 control where: 0=no change; 1=<10 epithelial cells shedding per lesion; 2=11–20 epithelial
159 cells shedding per lesion; 3=epithelial ulceration; 4=epithelial ulceration with severe crypt
160 destruction

161 4. *Cell infiltration*, presence of immune cells in submucosa: 0=none; 1=mild (2-43);
162 2=moderate (44-86); 3=severe (87-217).

163 The resulting variable, henceforth called “histopathological score”, has a maximum value of 13.

164 **Reverse Transcriptase-qPCR** - To identify the potential immunological pathways involved in
165 PA-derived protection, we examined the gene expression of several key immune markers
166 commonly associated with colitis. The mRNA gene expression for tumor-necrosis factor alpha
167 (TNF α), interferon-gamma (IFN γ), resistin-like molecule beta (Relm- β), regenerating islet-
168 derived protein 3 (RegIII- γ), transforming growth factor beta (TGF- β), chemokine C-X-C motif
169 ligand 9 (Cxcl9), and claudin 10 (Cldn10) were measured in colon tissues. Total RNA was
170 purified from tissues using Qiagen RNEasy kits (Qiagen) according to the manufacturer’s
171 instructions with an additional initial bead beating step (3x30 seconds, 30 Hz) on a Retsch
172 MixerMill MM 400 homogenizer. Next, cDNA was synthesized using the iScript cDNA Synthesis
173 Kit (Bio-Rad) in 10 μ l reactions. The RNA and cDNA products’ purity and quantity were
174 assessed by a NanoDrop spectrophotometer (Thermo Scientific). The cDNA products were
175 normalized to ~ 40 ng/ μ l with DNase free sterile water prior to qPCR reactions.

176 A total of 10 μ l RT-qPCR reactions consisted of: 0.2 μ l of each forward and reverse primers
177 (10mM), 5 μ l of Sso Fast Eva Green Supermix (Bio-Rad), 3.6 μ l DNase free water, and 1 μ l of
178 cDNA template. Reactions were run in triplicates using the Bio-Rad CFX96 Touch thermocycler
179 and analyzed using Bio-Rad CFX Maestro software 1.1 (v4.1). The median quantitation cycle
180 (Cq) value from each sample was used to calculate the $2^{-\Delta\Delta C_t}$ based on the reference gene
181 TATA box binding protein (Tbp). A list of all the primer sets, their melting temperature,
182 efficiencies, and detailed thermocycler protocol used in this study are described in
183 Supplementary Material 6.

184 **Short-chain fatty acids** - SCFAs, a byproduct of microbial fermentation, are an essential
185 component of a healthy gut environment (reviewed in (23)). They not only serve as a primary
186 food source for the colonocytes, but have immunogenic properties that, in concert with the host
187 immunity, are integral in maintaining gut homeostasis. We previously showed that in healthy
188 humans, cardiorespiratory fitness was positively correlated with fecal butyrate (16), a SCFA with
189 known anti-inflammatory properties in the gut (24). We therefore hypothesized that SCFA
190 profiles of VWR mice would differ from SED, favoring the production of beneficial butyrate that
191 may be involved in protection against colitis. We therefore analyzed SCFA (acetic, propionic,
192 heptanoic, valeric, caproic, and butyric acids) in cecal tissues by gas chromatography (GC) as
193 described previously in (25). In brief, ~50 mg of stool was homogenized with isopropyl alcohol,
194 containing 2-ethylbutyric acid at 0.01 % v/v as internal standard, at 30 Hz for 13 min using metal
195 beads. Homogenates were centrifuged twice, and the cleared supernatant was injected to Trace
196 1300 Gas Chromatograph, equipped with Flame-ionization detector, with AI1310 autosampler

197 (Thermo Fisher Scientific) in splitless mode. Data was processed using Chromeleon 7 software.
198 Half of the cecal tissue was freeze dried to measure the dry weight, and measurements are
199 expressed as $\mu\text{mol/g}$ dry weight (d.w).

200 **DNA extraction and 16S rRNA amplicon preparation** - The effects of PA on the intestinal
201 microbiome has recently risen as an area of great interest (Reviewed in (26)). To date, several
202 studies in mice have shown significant changes to the microbiome associated with either VWR
203 or forced treadmill running (19, 27–29). Allen *et. al* (30) further showed that transplanting the
204 microbiome of exercised mice into germ-free mice conferred protection against dextran-sodium-
205 sulfate (DSS)-induced colitis, highlighting the importance of PA-derived changes in the
206 microbiome. To examine such potential changes in gut microbiome, we surveyed the fecal
207 microbiome of our mice using high-throughput sequencing. DNA was extracted from fecal
208 samples using the QIAmp DNA Stool Mini Kit (Qiagen) according to the manufacturer's
209 instructions following 3 x 30 s of beat beating as before. Amplicon libraries were prepared
210 according to the Illumina 16S Metagenomic Sequencing Library Preparation manual. In brief,
211 the V3-V4 hypervariable region of the 16S bacterial rRNA gene was amplified using
212 recommended 341F and 805R degenerate primer sets, which create an amplicon of ~460 bp.
213 Amplicons were purified using AMPure XP beads and adapters and dual-index barcodes
214 (Nextera XT) were attached to the amplicons to facilitate multiplex sequencing. Following a
215 secondary clean-up step, libraries were quality controlled on an Experion automated
216 electrophoresis system (Bio-Rad), and sent to The Applied Genomic Core (TAGC) facility at the
217 University of Alberta (Edmonton, Canada) where they were normalized using fluorometric
218 method (Qubit, Thermo Fisher Scientific) and sequenced using the Illumina MiSeq platform with
219 a V3 reagent kits allowing for 2 x 300 bp cycles.

220 **Bioinformatics** - All bioinformatics processes were performed using a combination of R
221 statistical software (31) and the QIIME 2 platform (32) using the various build-in plugins
222 described below. Demultiplexed sequences were obtained from the sequencing facility and
223 primers removed reads using *cutadapt* (33). Sequences then underwent quality-filtering,
224 dereplication, denoising, merging, and chimera removal using DADA2 (34). The output of this
225 process is a feature table of amplicon sequence variants (ASV) that is a higher resolution
226 analogue of traditional OTU tables. To aid in removal of non-specific host contaminants, a
227 positive filter was applied to all reads using the latest available Greengenes (13_8) (35)
228 database (clustered at 88% identity). All ASVs were searched against the reference reads
229 using VSEARCH (36) and any that did not match the reference sequences at a minimum of
230 70% identity similarity at 70% alignment were discarded. For analyses encompassing
231 phylogenetic information, a phylogenetic tree was constructed using a SATé-enabled
232 phylogenetic placement (SEPP) technique as implemented in the *q2-fragment-insertion plugin*
233 (37) using a backbone tree build based on the SILVA (128) database (38). Taxonomic
234 classification of the ASVs were carried using IDTAXA (39). It has been proposed that the
235 functional repertoire of the gut microbiota is more sensitive to perturbation than taxonomic
236 changes, and therefore may be crucial in identifying underlying physiological signals (40). To
237 predict the functional potential and phenotype of the microbiome, we used BugBase (41) which
238 utilizes PICRUST's (42) extended ancestral-state reconstruction algorithm for metagenome
239 composition prediction. As these tools require sequences to be classified against the

240 Greengenes taxonomy assignments, we used VSEARCH to pick closed-reference OTUs from
241 our denoised feature table at 97% similarity threshold against the 99% identity clustered
242 Greengenes database.

243 **Statistical Analyses** - All statistical analyses were performed using R version 3.5.1 unless
244 stated otherwise. During the 3rd week of the experiment, the VWR animals were unintentionally
245 exposed to 3 days of irregular light-dark cycles as a result of an electrical malfunction with the
246 lighting in the animal room. While the exact nature of this disruption is not known, the wheel
247 running data during this period suggests a period of reduced activity. The issue was resolved by
248 the 3rd day and the animals did not display any signs of stress or irregular behavior; we
249 therefore consider this to be of minimal impact to the experiment. However, as a precaution, we
250 chose to analyze the data as a 4 x 1 (*groups*) factorial design rather than 2 x 2 (*activity x*
251 *genotype*) as we could not definitively eliminate the possibility that wheel running in this group
252 was impacted by the brief interruption.

253 **Wheel running** - To determine whether WT and *Muc2*^{-/-} ran similar distances throughout the
254 experiment, we first analyzed total weekly distances (km) run by each group across the 6 weeks
255 time using linear mixed-effects regression (LMER) using the *lme4* package with individual
256 animals set as the random effect and *groups* as the fixed effects. Homoscedasticity and linearity
257 of the models were assessed using diagnostic plots of the residuals.

258 **Body weights and food/water intake** - To monitor overall behavioral changes of mice as a
259 result of PA between WT and *Muc2*^{-/-} mice, we examined weekly body weights, food and water
260 intake across the 6 weeks. To account for natural differences in starting body weights, total
261 weight gained relative to starting body weights was calculated each week. Body weight, food
262 and water intake across the 6 weeks were each assessed separately using a repeated
263 measures LMER with *time* coded as a random effect and *groups* as a fixed effect. A Tukey HSD
264 post-hoc test with the Benjamini-Hochberg (BH) P adjustment method was used when an
265 overall significance (set as P<0.05) in the models were detected.

266 **Clinical and Histopathological Scoring** - We used a cumulative link model (CLM) with a logit
267 link to evaluate whether the disease score, and separately, the histopathological score differed
268 among treatment groups. This proportional odds type test is more appropriate for ordinal data
269 than classic linear regressions. For clinical scores, the model included *time* and *groups* as the
270 fixed effects, and individual animal ID as the random effect. For histopathological score, the total
271 average score of the MSED and MVWR groups were separately analyzed using the same
272 method, but without the *time* random effect. We implemented the analyses using the *ordinal* R
273 package.

274 **Colon mRNA gene expression** - To test whether the expression of colonic mRNA genes
275 differed across groups, we first explored the overall abundance of all surveyed genes
276 simultaneously using an ordination method. The Euclidean distances of Hellinger-transformed
277 relative gene expression values were ordinated onto a principal component analysis (PCA) plot.
278 When a clear clustering was observed based on group assignments, differences in variance
279 across these groups were assessed using a permutational multivariate analysis of variance

280 PERMANOVA test using the *vegan* package, and pairwise differences calculated using
281 *pairwiseAdonis* with BH adjustment for multiple testing. For differential abundance testing of
282 each cytokine, a multivariable generalized linear model (GLM) test was carried out using the
283 *mvabund* package (43). This fits separate GLMs to each cytokine while accounting for non-
284 independence and adjusting for multiple testing. The negative binomial distribution assumption
285 was selected for the model and the mean-variance plot was used to assess the model fit. A
286 Kruskal-Wallis post-hoc test was carried on individual genes when significance was detected in
287 the overall model. Pairwise comparisons across groups were carried out using Conover's test
288 for multiple comparisons within the *PMCMRplus* package.

289 **Short-chain fatty acids** - Similar to the cytokine data analysis, to test the differences in
290 abundance of SCFAs across groups, concentrations of various cecal SCFA were assessed
291 using a multi-GLM test. Post-hoc tests were carried out on individual SCFAs identified as
292 significant from the univariate results from the global model.

293 **Microbial Analysis** - Following our previous observation in humans that showed distinct
294 microbial community characteristics and metagenomic functions associated with higher
295 cardiorespiratory fitness, we evaluated whether similar patterns emerged in mice. Community
296 structural patterns of fecal bacteria across samples (β diversity) were explored using the *q2-*
297 *DEICODE* plugin (44). DEICODE is a compositionally aware method that utilizes a form of
298 robust Aitchison distances to create a species abundance distance matrix of ASVs which can
299 then be projected onto a PCA biplot. We visualized this using the Emperor interactive graphic
300 tool (45). To reveal possible group differences, a PERMANOVA (46) test was conducted on all
301 groups across time. Pairwise testing was then followed using a Kruskal-Wallis test with a BH
302 adjustment to control for false discovery rate (FDR).

303 The overall within-sample diversity (α diversity) for each sample was estimated based on the
304 species richness, Simpsons, and Shannon indices using the *DivNet* package (47). For each
305 group, the difference between a sample's week 6 and week 0 diversity score was calculated
306 and used to determine whether those changes differed from zero (Wilcoxon test) as well as
307 other groups (ANOVA).

308 Differential abundance testing of individual taxa was performed using the *CornCob* package
309 (48).


310 BugBase was used to determine high-level phenotypes of bacterial communities based on the
311 following default traits: Gram negative vs. Gram positive, biofilm forming, mobile element
312 containing, oxidative stress tolerance, pathogenic potential, and oxygen utilizing. Pre- and post-
313 treatment differences in relative abundances of these elements were tested in each group using
314 a Kruskal-Wallis test with Benjamini-Hochberg adjustment of P values to control FDR.

315

316 **Results**

317 **Wheel running** - For unknown reasons, one animal from each group did not run on the wheels
318 and so were excluded from further analyses. The WT group ran an average (SD) of 46.6 (18.4)
319 km in total throughout the 6 weeks, while the *Muc2*^{-/-} animals ran slightly less at 40.7 km (21.5)
320 which correspond to ~ 1.3 and 1.1 km/day, respectively. While the WT showed a general trend
321 towards more wheel running, the differences were not statistically significant (Figure 1A) likely
322 due to the highly variable nature of running data.


323 **Body Weights, food and water intake** - Weight gain was not significantly different across
324 activity levels, however as expected *Muc2*^{-/-} mice gained less weight throughout the 6 weeks
325 (Figure 1B). The mean (\pm SE) total weight gain of each group was: SED 33.12 \pm 2.66 %, VWR
326 26.98 \pm 2.14%, MSED 19.18 \pm 1.96%, and MVWR 19.59 \pm 2.99% relative to their starting body
327 weights in grams. By the final week, VWR animals had gained ~ 6% less total weight compared
328 to their SED counterpart (P=0.09). Food intake was not statistically different between groups
329 across the 6 weeks (Supplementary Material 1A). *Muc2*^{-/-} mice drank significantly more water
330 than WT animals (Beta coefficient (B): 5.4, P<0.001) throughout the 6 weeks. Wheel running
331 was associated with increased water intake in WT (B: 5.3; P<0.01) and to a lesser extent in
332 *Muc2*^{-/-} mice (B:1.9; P<0.86) (Supplementary Material 1B).



333

334 **Figure 1. Weekly measures of relative weight gain and wheel running**

335 Longitudinal measurements of A) average accumulated distance ran, B) relative weight gain
336 compared to week 0. Linear mixed models were used with *week* and *animals* set as random
337 effects. There were no significant effects of wheel running in either wheel running or weight
338 gain. * indicates a significant ($P < 0.05$) main effect between genotypes.



339

340

341 **Supplementary material 1. Weekly measures of food and water intake**

342 Longitudinal measurements of A) average weekly food intake, and B) average weekly water
343 intake. Linear mixed models were used with *week* and *animals* set as random effects. There
344 were no significant effects of wheel running in either food or water intake. * indicates a
345 significant ($P < 0.05$) main effect between genotypes.


346

347

348 Histopathological and clinical scores

349 We found a modest but significant difference in disease score between MVWR and MSED
350 groups (Coefficient estimate (CE): -1.67; $P < 0.01$) across the 6 weeks, indicating reduced clinical
351 signs in the running animals. However, post-hoc tests carried out each week showed no
352 significant difference between groups (Figure 2A). The differences between groups appear to
353 increase with time, with the largest difference appearing at week 6 (CE: -2.0, $P = 0.063$).
354 Histopathological scores based on H&E sections showed no differences among the groups
355 (Figure 2B).

356




357

358 **Figure 2. Assessment of severity of colitis signs in *Muc2*^{-/-} mice**

359 Comparison of A) clinical disease scores across 6 weeks, and B) histopathological scores in
360 *Muc2*^{-/-} animals at terminus. C) Representative colon images of H&E stained sections from
361 MSED and MVWR mice. No significant differences were observed between groups in either
362 measurements. Values are shown as means \pm SE.

363 **Short-chain fatty acids** - The results of the GLM indicated a significant group effect (Dev:
364 14.83, $P < 0.01$) and the univariate tests showed significant differences in acetate, propionate,
365 butyrate, and valerate across groups. The results of the post-hoc analyses on these SCFAs and
366 total SCFA are shown in Figure 3. Total SCFA concentration was significantly higher in VWR
367 mice than all other groups, while SED mice had similar total SCFA to both *Muc2*^{-/-} groups. VWR
368 mice also had significantly higher total acetate and butyrate than all the other groups and higher
369 propionate than SED. Overall, the major difference between *Muc2*^{-/-} and WT animals was the
370 significantly reduced levels of butyrate in *Muc2*^{-/-} mice and inversely, higher levels of propionate.
371 Valerate, caproate, and heptanoate were similar across all groups. In terms of relative
372 abundances, the main differences between *Muc2*^{-/-} and WT were the higher propionate and
373 lower butyrate proportions in *Muc2*^{-/-} animals. Importantly, the proportion of butyrate in VWR
374 mice (~12 %) was significantly higher than those in SED (~7.9 %).




375

376 **Figure 3. Cecal SCFAs composition**

377 Cecal tissues analyzed for SCFAs composition using gas chromatography. The bottom and top
378 of boxes are the first and third quartiles, the middle band inside the boxes is the median, the
379 whiskers contain the upper and lower 1.5 interquartile range (IQR). * denotes significantly
380 different pairs (adjusted $P < 0.05$)
381

382 **Colon mRNA gene expression** - The exploratory PCA plot showed clear separation of the WT
383 vs. *Muc2*^{-/-} animals along the first principal component (PC1) axis which accounted for 41.7% of
384 the variation (Supplementary Material 2). Further clustering between the SED and VWR groups
385 but not between MSED and MVWR was observed along PC2, which accounted for an additional
386 17.7% of the variance. The result of the PERMANOVA test confirmed these observations
387 revealing a clear separation amongst groups (F, 10.513; P <0.01). The pairwise comparison test
388 shows a statistically significant separation between all pairs except between MSED and MVWR.
389 The global multi-GLM model showed a significant difference (adjusted P = 0.001) across groups
390 with the univariate tests showing a significant difference in all genes across groups. Notably,
391 VWR mice had significantly lower TNF- α , TGF- β , IFN- γ , and RegIII- γ compared to SED mice
392 (Figure 4); no changes were detected between MVWR and MSED animals. *Muc2*^{-/-} animals had
393 increased concentrations of IL-10, RELM- β , CXCL9, RegIII- γ , and TNF- α compared to their WT
394 counterparts.




395

396 **Supplementary Material 2. PCA of colonic mRNA gene expression**

397 The Hellinger-transformed Euclidean distances of cytokine abundance data are projected onto
398 PCA. Results of the PERMANOVA test showed a significant (F, 10.513; P <0.01),
399 permutation=999) separation between all groups except between MSED and MVWR.

400

401




402

403 **Figure 4. Colonic mRNA gene expression**

404 The relative mRNA gene expression of selected pro- and anti-inflammatory mediators in colon.
405 The bottom and top of boxes are the first and third quartiles, the middle band inside the boxes is
406 the median, the whiskers contain the upper and lower 1.5 interquartile range (IQR). * denotes
407 significantly different (adjusted $P < 0.05$)

408 **Bacterial community analysis.** Beta diversity: The PERMANOVA test showed a significant
409 difference between *Muc2*^{-/-} and WT animals corresponding to clear clustering observed between
410 these groups on the PCA plots (Figure 5A). Importantly however, there was a significant
411 distance between SED and VWR animal clusters prior to treatment assignment. This fact
412 strongly suggests the presence of a batch effect in our experiment which is likely explained by
413 the fact that the VWR animals were purchased at different times compared to the other groups
414 and their microbiome sequenced separately. As batch-effects are a well-known issue in short-
415 read sequencing experiments (49), differences across groups are then likely confounded by
416 this. Therefore, to mitigate this effect, in all subsequent analyses, changes in microbiome are
417 either only compared within the same group across time, or the change within each group is
418 compared to changes in other groups. Pairwise analysis of each group comparing their week 0
419 to week 6 profiles showed changes in overall microbiome variation in all animals across time. In
420 *Muc2*^{-/-} animals, these changes were non-uniform and did not follow a predictable pattern
421 (Figure 5C). WT animals on the other hand showed a clear and unidirectional change (clear
422 clustering) in their overall microbiome (Figure 5B). A significant shift in community structure of
423 both VWR and SED animals based on the Aitchison distances was observed by week 6
424 (Pseudo F= 75.2; P=0.001, permutations=999), and these changes were significantly different
425 from each other. These shifts suggest a distinct change in the structure of the microbiome as a
426 function of time as well as physical activity in WT animals. We next compared the magnitude of
427 change ($\Delta = \beta_{wk6} - \beta_{wk0}$) across all groups and found no significant differences (Supplement
428 Material 3) between them.

429




430

431 **Figure 5. Changes in fecal microbiome composition across time and physical activity.**

432 PCA biplot of Robust Aitchison distances visualized where data points represent individual mice
 433 colored by their group designation, with spheres corresponding to samples at week 0 and rings
 434 representing week 6. The vectors represent the topmost significant ASV loadings driving
 435 differences in the ordination space. A) While the *Muc2*^{-/-} mice appear to cluster together
 436 regardless of activity status, the WT mice appear to be separated at week 0, suggesting the
 437 presence of a batch effect, therefore, further analyses are focused on the change across time in
 438 each group separately. B) Significant differences were detected as a function of both time and
 439 activity in WT mice as determined by PERMANOVA test (pseudo F= 75.2; P=0.001,
 440 permutations=999). Pairwise test showed differences between all groups (P<0.001). C) No
 441 group differences were detected in *Muc2*^{-/-} as determined by a PERMANOVA test (pseudo F=
 442 0.47; P=0.86, permutations=999)

443

444



445


446

447 **Supplementary Material 3. The magnitude of change in beta diversity across time.**

448 Robust Aitchison distances were calculated using DEICODE and the change in beta diversity
449 across time within each group was compared to others. All groups demonstrated some change
450 in overall beta diversity across time (values > 0), however the magnitude of change was not
451 different across groups.

452

453 Alpha diversity: The difference in change of alpha diversity estimates between week 6 and week
454 0 showed no significant change across any group (Figure 6A-C). The WT mice had a
455 significantly higher ($P < 0.001$) overall diversity than *Muc2*^{-/-} animals in all examined diversity
456 indexes: species richness, Shannon (Figure 6D), and Simpson index.



457

458 **Figure 6: Change in alpha diversity following 6 weeks of voluntary wheel running**


459 Values are differences between week 6 and week 0. Panels A-C, each group's change in alpha
460 diversity after 6 weeks was compared to its own week 0 values, as well as to other groups. No
461 differences were observed across any groups. D) The overall Shannon diversity of WT mice is
462 significantly higher than those of *Muc2*^{-/-} mice

463

464

465 Differential abundance testing: Only WT animals showed statistically significant changes in
466 relative abundance of individual taxa across time. In SED animals, 21 significant taxa were
467 changed by week 6, and 20 were different in VWR animals (Figure 7). Of these 41 total
468 changed taxa, only 4 were common across both groups (Supplementary Material 4).
469 Interestingly, the relative abundance of these 4 taxa changed in the same direction, suggesting
470 the possibility of an age-driven effect. These changes were an increase in the genus
471 Ruminiclostridium5, decrease in genera Negativibacillus and Harryflintia, and decrease in the
472 Lachnospiraceae family.

473




474

475 **Figure 7. Significant differences in fecal ASVs across time in WT mice.**

476 WT mice, but not *Muc2*^{-/-}, showed a significant change in relative abundance of several ASVs
 477 (threshold set at FDR P < 0.01) across time. Different ASVs are changed in VWR compared to
 478 SED mice. The points on the plot represent the mean change in relative abundances of each
 479 ASVs at week 6 compared to week 0, bars represent the 95% prediction intervals.

480




481

482 **Supplementary Material 4:** Venn diagram representing the number of unique ASVs detected to
483 be differentially abundant across time in WT mice. The number in each circle represents the
484 total number of ASVs that were statistically different at week 6. The overlapping region
485 represents the number of significant ASVs that were changed in both groups. These 4 common
486 taxa were changed in a similar fashion in both groups suggesting a possible age-driven effect,
487 independent of wheel running. Arrows besides taxon name represent the direction of change at
488 week 6 relative to week 0.

489

490

491 Predicted phenotypic traits: BugBase's prediction of each community's phenotypic traits suggest
492 major differences between WT and *Muc2*^{-/-} animals (Supplementary Material 5). Bacterial
493 communities in *Muc2*^{-/-} mice were composed of significantly higher abundances of Gram
494 negative, aerobic, and facultative anaerobic bacteria with a higher potential for biofilm formation.
495 Their communities also housed less bacteria with mobile elements and had an overall lowered
496 tolerance for oxidative stress. At week 6, only VWR mice showed significant changes in their
497 bacterial phenotypes compared to week 0. Their communities showed lower average
498 abundances of mobile-containing (~12 %, P<0.05) and Gram-positive (~14 %, P<0.001)
499 bacteria (Figure 8).



500

501

502 **Figure 8. Change in predicted phenotypic traits of microbial communities in VWR mice**
503 **following 6 weeks of wheel running**

504 BugBase was used to predict the composition of microbial communities based on their bacterial
505 traits. Only VWR mice showed a statistically significant change in overall microbial community
506 traits of A) those containing a mobile element, and B) Gram positive bacteria, across time.

507

Characteristic	SED			VWR		
	wk0, N = 8 ¹	wk6, N = 8 ¹	p-value ²	wk0, N = 8 ¹	wk6, N = 7 ¹	p-value ²
Aerobic	0.007 (0.005, 0.009)	0.002 (0.001, 0.006)	0.12	0.009 (0.005, 0.016)	0.041 (0.015, 0.061)	0.11
Anaerobic	0.962 (0.960, 0.965)	0.968 (0.941, 0.971)	0.6	0.953 (0.949, 0.957)	0.939 (0.911, 0.963)	0.6
Contains_Mobile_Elements	0.83 (0.82, 0.84)	0.84 (0.73, 0.89)	0.8	0.87 (0.84, 0.91)	0.82 (0.76, 0.82)	0.005
Facultatively_Anaerobic	0.0019 (0.0016, 0.0029)	0.0010 (0.0005, 0.0017)	0.093	0.003 (0.001, 0.014)	0.001 (0.000, 0.001)	0.073
Forms_Biofilms	0.003 (0.003, 0.004)	0.001 (0.001, 0.004)	0.14	0.014 (0.009, 0.016)	0.043 (0.014, 0.058)	0.2
Gram_Negative	0.19 (0.17, 0.21)	0.17 (0.12, 0.31)	0.8	0.16 (0.12, 0.19)	0.26 (0.21, 0.33)	0.015
Gram_Positive	0.81 (0.79, 0.83)	0.83 (0.69, 0.88)	0.8	0.84 (0.81, 0.88)	0.74 (0.67, 0.79)	0.015
Potentially_Pathogenic	0.41 (0.37, 0.45)	0.35 (0.33, 0.53)	0.7	0.36 (0.35, 0.41)	0.42 (0.39, 0.47)	0.064
Stress_Tolerant	0.965 (0.946, 0.977)	0.988 (0.970, 0.993)	0.2	0.975 (0.969, 0.981)	0.979 (0.972, 0.982)	0.6

¹Statistics presented: median (IQR)

²Statistical tests performed: Wilcoxon rank-sum test

508

Characteristic	MSED			MVWR		
	wk0, N = 8 ¹	wk6, N = 8 ¹	p-value ²	wk0, N = 8 ¹	wk6, N = 8 ¹	p-value ²
Aerobic	0.29 (0.27, 0.34)	0.32 (0.30, 0.34)	0.7	0.34 (0.31, 0.38)	0.33 (0.30, 0.34)	0.8
Anaerobic	0.66 (0.62, 0.71)	0.65 (0.63, 0.68)	>0.9	0.63 (0.60, 0.67)	0.65 (0.63, 0.66)	0.6
Contains_Mobile_Elements	0.59 (0.55, 0.74)	0.60 (0.56, 0.67)	0.7	0.59 (0.57, 0.61)	0.60 (0.57, 0.76)	0.8
Facultatively_Anaerobic	0.011 (0.007, 0.020)	0.010 (0.007, 0.012)	>0.9	0.013 (0.006, 0.018)	0.012 (0.010, 0.013)	>0.9
Forms_Biofilms	0.30 (0.27, 0.35)	0.33 (0.30, 0.34)	0.8	0.34 (0.31, 0.38)	0.34 (0.31, 0.35)	0.8
Gram_Negative	0.77 (0.64, 0.79)	0.76 (0.69, 0.81)	>0.9	0.77 (0.73, 0.81)	0.81 (0.69, 0.82)	0.5
Gram_Positive	0.23 (0.21, 0.36)	0.24 (0.19, 0.31)	>0.9	0.23 (0.19, 0.27)	0.19 (0.18, 0.31)	0.5
Potentially_Pathogenic	0.53 (0.40, 0.56)	0.50 (0.43, 0.53)	0.7	0.51 (0.49, 0.54)	0.54 (0.33, 0.57)	0.4
Stress_Tolerant	0.970 (0.965, 0.982)	0.987 (0.973, 0.991)	0.3	0.983 (0.977, 0.994)	0.977 (0.949, 0.983)	0.14

¹Statistics presented: median (IQR)

²Statistical tests performed: Wilcoxon rank-sum test

509

510

511 **Supplementary Material 5. Summary statistics of predicted microbial traits**

512 Bugbase was used to predict the phenotypic traits of microbial communities based on 16S

513 marker genes. Values in the table are relative abundances of bacteria with the associated trait.

Discussion

***Muc2*^{-/-} mice vastly differ from WT in their colonic cytokine, SCFA, and microbial profiles**

Muc2^{-/-} mice displayed clinical and histological symptoms of moderate colitis corresponding to the expected severity of this model at 11 weeks of age in our facilities. The colonic gene expression of inflammatory cytokine TNF- α , and the mucosal defense factor RELM- β , as well as antimicrobial peptide RegIII- γ were upregulated in *Muc2*^{-/-} animals, as observed previously (15). Notably, the anti-inflammatory cytokine IL-10 was overexpressed in *Muc2*^{-/-} compared to C57BL/6 WT. While in a healthy state, the expression of IL-10 may be associated with increased tolerance to inflammatory events, in *Muc2*^{-/-} animals, this upregulation is essential in the host's efforts at suppressing the excessive inflammation resulting from continuous exposure to bacterial ligands. Indeed, *Muc2*^{-/-} + IL-10^{-/-} double knock-out mice show highly exacerbated colitis clinical signs (50) compared to deletion of either genes separately. The increase in IL-10 also has been previously observed in chemical models of colitis (9, 11). We further detected significant overexpression of CXCL9 in *Muc2*^{-/-} animals. CXCL9 is a chemokine involved in regulating leukocyte trafficking, likely in response to exposure of bacterial ligands to host cells. CXCL9 overexpression also has been reported in IBD patients (51). Overall, the cytokine profile of *Muc2*^{-/-} animals reflect those expected in human IBD.

Muc2^{-/-} mice born without a normal mucus layer house drastically less diverse and different bacterial communities than WT mice, as evident by the clear clustering of this group from WT animals in our PCA plots. Similar to patterns seen in IBD patients (52), or chemically-induced murine colitis (53, 54), *Muc2*^{-/-} animals had an overall reduced α -diversity compared to their WT counterparts. The dominant taxa in WT mice were generally of the *Bacteroides* genus, Clostridiales order, and Lachnospiraceae family, while *Muc2*^{-/-} animals were dominated by members of the Muribaculaceae family (formerly known as S24-7 (55)) and Akkermansia genus of the Verrucomicrobia phyla. While our taxonomic classifier was unable to confidently differentiate between the 2 sole species (Akkermansia muciniphila and Akkermansia glycaniphila) within this genus, it is reasonable to assume that the observed taxa were *A. muciniphila* as *A. glycaniphila* has, to date, only been isolated from python feces (56). *A. muciniphila* is perhaps the most surprising finding in this group as this species is known -and named- for its ability to degrade mucin, and is broadly considered as a beneficial bacterium in a variety of chronic diseases including IBD (57–59). The broader implications of this finding are beyond the scope of the present study. However, it does warrant the reassessment of the characterization of *A. muciniphila* as a mucin loving species to one that thrives in the absence of mucin. The bacterial phenotypic traits of *Muc2*^{-/-} animals were predicted to be higher in abundances of Gram-positive, aerobic, and biofilm forming groups compared to WT mice. Lastly, the cecal SCFA of *Muc2*^{-/-} mice were composed of significantly less butyrate and higher propionate concentrations compared to SED animals. The increased propionate levels in these animals is likely associated with the high abundances of *A. muciniphila*, a prominent propionate producer (60, 61). Overall, we found the *Muc2*^{-/-} model of colitis to capture many components of human IBD, especially those with impaired mucosal integrity.

Wheel running in *Muc2*^{-/-} mice does not reduce the severity of chronic colitis

Contrary to our primary hypothesis, we found that 6 weeks of wheel running in *Muc2*^{-/-} mice did not improve the severity of clinical signs, histopathological scores, colonic expression of inflammatory cytokines, or abundances of cecal SCFAs, and did not alter the gut microbial composition in a consistent manner. These findings contrast others that show protective effects of VWR or forced treadmill running in chemically-induced models of colitis (8, 10, 11, 62). The fundamental difference between those studies and ours is in the model of colitis used. Previously, VWR was initiated in healthy animals prior to disease induction with chemical toxins, whereas in our study, wheel running is imposed over an existing disease state as a therapeutic intervention. This would suggest that PA prior to disease onset primes various components of intestinal health, enhancing its tolerance to injury. The effects of PA following disease-onset on the other hand, are either abolished or are overwhelmed by stronger disease signaling. It is also possible that the physiological benefits of PA depend on the presence of a healthy mucosal layer. This is supported by our findings that wheel running in WT but not *Muc2*^{-/-} animals leads to significantly lower levels of pro-inflammatory colonic cytokines, increased anti-inflammatory IL-10, and increased levels of beneficial SCFAs. Given that UC patients typically have defective and thinning colonic mucosal layers, this would suggest that exercise prescription in these populations may have limited direct benefits on their intestinal health. However, the well-documented benefits of exercise are instituted across various other sites and systems of the body, which may indirectly result in improving primary and secondary disease symptoms through other pathways not accounted for in this experiment. For example, PA as a primary intervention has been associated with improved quality of life in IBD patients (63) and inversely correlated with loss of bone mass density, a common risk factor in this population (64, 65).

VWR significantly attenuates pro-inflammatory, and upregulates anti-inflammatory cytokines in WT mice

Compared to SED animals, the wheel running mice showed lower levels of inflammatory cytokines TNF- α , IFN- γ , and TGF- β , all of which have been implicated in IBD (66). TNF- α is perhaps the most studied cytokine in relation to IBD as it plays a crucial role in innate and adaptive immunity and is directly involved in apoptotic processes in the intestines (67). It is found in significantly higher abundances in IBD patients (68) as well as murine colitis (69), making its regulation an obvious target for disease management. In fact, TNF- α inhibition using monoclonal antibodies is the most common target of biological therapies for moderate to severe IBD. The role of IFN- γ in colitis pathogenesis is less consistent across the literature, however its overproduction has been shown in CD (70, 71) and UC patients (72). In DSS-induced colitis models, neutralization antibodies against IFN- γ significantly reduced disease severity(73), while IFN- γ ^{-/-} mice were completely protected from disease clinical signs (74). Anti-IFN- γ antibody treatments in human IBD are less effective however, with their efficacy dependent on baseline C-reactive protein levels (75), highlighting the need for treatment personalization. TGF- β is a pleiotropic cytokine that is ubiquitously produced by many cells and is involved in various immune functions including both anti- and pro-inflammatory actions. These include suppression of immune responses through recruitment of Tregs which in turn produce IL-10, but TGF- β can also elicit potent Th17 responses to combat extracellular bacteria (76). TGF- β is found in higher

concentrations in intestines of IBD patients (77, 78), due to increased exposure of microbial ligands to host epithelial cells. Inversely, the attenuated levels of this cytokine in our VWR animals then may reflect a decrease in bacterial antigen exposure to the IEC suggesting reduced levels of host-microbe interactions in the mucosa. Alternatively, reduced TGF- β could also indicate reduced Treg activity in VWR mice, however, the increase in Treg derived IL-10 in these animals does not support this notion. IL-10 is an anti-inflammatory cytokine ubiquitously secreted by Tregs and is the primary driver of immunosuppressant actions in the intestines. Polymorphism in IL-10 promoters have been linked to IBD, making IL-10 supplementation a potential target for IBD therapy, however, clinical studies of IL-10 therapy to date have not been significantly effective (79). The significant increase in IL-10 in VWR mice suggests higher Treg activity which is associated with reduced inflammation. This is in agreement with others who showed a significant increase in murine intestinal IL-10 following treadmill running or swimming (80, 81). However, it is unclear whether this reflects a beneficial increase in anti-inflammatory events, or simply an adaptive response to changes in the microbial composition. Gram-negative bacteria preferentially stimulate IL-10 production and are associated with higher virulence due to increases in abundance of lipopolysaccharides bound to their cell walls (82). The higher expression of IL-10 in VWR animals then is likely correlated with increased abundance of Gram-negative bacteria observed in these mice. Further investigations are needed to determine the consequence of these changes. Taken together, the reduction of these pro-inflammatory cytokines and increase in anti-inflammatory IL-10 in VWR animals suggests a primed anti-inflammatory state in healthy WT but not diseased intestines, marking them as potentially important targets for prevention and remission maintenance therapy.

VWR significantly augments SCFAs content in WT but not *Muc2*^{-/-} mice

SCFAs are metabolic by-products of bacterial fermentation of dietary fibers in the colon and are involved in various physiological processes of the host. Aberrant intestinal SCFAs content has been implicated in various diseases such as irritable bowel syndrome, cardiovascular disease, certain cancer types, and IBD (83–85). The most abundant of these, acetate, propionate, and butyrate, which make up over >95% of SCFA in humans (23), are markedly decreased in IBD patients (86), while their exogenous delivery can reduce inflammation *via* inhibition of TNF- α release from neutrophils (84, 87). Overall, increases in these SCFAs, especially butyrate, appear to positively influence IBD (88). We found an overall higher abundance of total cecal SCFAs, acetate, butyrate, and propionate in response to wheel running in WT but not *Muc2*^{-/-} animals. This is in accordance with others showing higher butyrate concentrations in wheel running in rats (89), following exercise training in lean humans (30), and elite athletes (90). We've also previously observed a positive association between higher butyrate levels and VO₂ peak in healthy humans (16). The increase in these SCFAs may simply reflect higher energy demands of colonocytes which utilize SCFAs as their primary energy substrate. Interestingly, when we analyzed SCFAs content in relative abundances, we saw a significant increase in relative abundance of butyrate, but not acetate, or propionate. This suggests a preference in VWR animals for production of butyrate and its accompanying anti-inflammatory properties. These findings further support the patterns of anti-inflammatory priming we observe in these animals, contributing to an overall healthier intestinal environment following physical activity. The mechanisms behind PA-induced changes in SCFA are not known,

however, given that SCFA are primarily produced by the intestinal microbiota, it is highly likely that changes in SCFA are linked to the observed changes in the microbiome. SCFA affects microbiota dynamics as they are directly involved in chemical balance and pH regulation of the intestines (91) and in turn the microbiota can also affect SCFA production and use, establishing a bidirectional affiliation.

Wheel running has limited but significant effects on the intestinal bacterial composition of WT but not *Muc2*^{-/-} mice

In this study, neither time nor wheel running had any effect on any alpha diversity metrics measured. The effects of PA on alpha diversity is not consistent within the literature. For example, the findings here are in contrast to our own previous observations in healthy humans that showed a significant correlation between alpha diversity and cardiorespiratory fitness (16). Others have also reported that elite athletes have higher alpha diversity than sedentary controls (92), or that exercise training in mice leads to increased Shannon diversity (93, 94). However, in agreement with the current experiment, PA has been shown to have no effect on alpha diversity in mice (29, 95, 96), rats (97), and humans (30, 98). The reasons for these discrepancies are not clear, though multiple factors such as differences in animal vendors and facilities, DNA extraction methods and sequencing, bioinformatics analysis, and statistical testing methods, are likely involved. Additionally, one particularly important consideration in comparing animal models of PA is the total volume of activity performed. For example, across the aforementioned studies utilizing wheel running in mice, we noticed a wide range (~ 2.5-10 km) of average daily running distances reported. Different volumes of PA are likely to elicit different physiological responses which can extend to the microbiome.

Comparisons of the across-samples diversity (beta diversity) in *Muc2*^{-/-} animals showed no patterns of change as a function of time or wheel running. In WT animals, however, the change in Aitchison distances between week 6 and 0 were significantly different between VWR and SED groups, indicating both time and wheel running as important factors in the observed shift in community composition. The magnitude of this change across time between the groups however was not different.

Univariate analyses of individual taxa in *Muc2*^{-/-} animals also showed no significant changes in any microbial clades across either groups. A lack of significant change in these animals suggests that the presence of a healthy mucosal layer is required to mediate PA-induced changes in community composition in the colon. In WT animals, the relative abundances of over 20 taxa in each group were significantly different by week 6 (Figure 7), with only four of those taxa common to both VWR and SED groups. The changing taxa in either group belonged primarily to the Ruminococcaceae and Lachnospiraceae families, with some species increasing while others decreased. Notably, In SED animals, 5 species from the *Bacteroides* genus were decreased by week 6, while no changes in this genus were detected in VWR animals. Species within the *Bacteroides* genus are Gram-negative, obligate anaerobes that are among the most abundant found within the mammalian intestine and carry important functions such breaking down of complex glycans, refining the gut environment by reducing intracellular oxygen levels, and preventing the colonization of opportunistic pathogens (99). *Bacteroides* spp. are also one

of the primary propionate producers in the mammalian gut (100), therefore, the observed reduction in members of this group in SED animals may in part explain their lower propionate levels compared to VWR mice. Given that we were unable to classify these ASVs to the species level, it is difficult to speculate further on the biological implications of these observations. Perhaps the most studied species in this group, *Bacteroides fragilis*, has been shown to be protective against DSS colitis in mice by stimulating IL-10 expression (101, 102). Given that we also observed significantly lower IL-10 expression in SED mice, it is reasonable to speculate that at least one of the unclassified Bacteroides ASVs in this group is *B. fragilis* and linked to the relatively lower expression of this protective cytokine in those animals.

Analyzing the bacterial consortia based on their predicted phenotypic traits revealed additional information regarding the effect of wheel running on the overall community. Following wheel running, WT but not *Muc2*^{-/-} mice, had significant reduction (~ 14%) in total abundance of Gram-positive bacteria. This is supported by the observed decreases in several members of the Gram-positive Ruminococcaceae in these mice, as well as the attenuated expression of RegIII-γ, an antimicrobial peptide that specifically targets the surface peptidoglycan layer of Gram-positive bacteria. The implications of this phenotypic shift in microbiota of healthy individuals is not known, but may provide a clue for understanding the adaptations of the intestinal environment to the physiological stresses of PA. Furthermore, mirroring the shift in Gram-positive phenotype was the decreased relative abundances of bacteria containing mobile elements. These refer to microevolutionary processes such as transposons i.e. segments of DNA with the ability to move locations within the genome, and bacterial plasmids which are involved in horizontal gene transfer. These events are typically associated with sharing of virulence factors between bacterial cells and increased resistance to antibiotics. The higher abundances of mobile elements in bacteria from these mice is likely not indicative of antibiotic-resistance but rather associated with higher abundances of Gram-negative bacteria representing more mobile-elements. The results of these predictions should be interpreted with caution however, as these mobile elements can rapidly become population specific within an individual thus precluding inference across similar experimental groups (103).

Summary

In contrast to our hypothesis we found that 6 weeks of wheel running did not ameliorate any clinical signs of colitis in *Muc2*^{-/-} animals, nor did it influence any components of the intestinal environment such as expression of various cytokines and production of SCFA. Wheel running in healthy WT C57BL/6 mice on the other hand, imposed various physiological effects on the gut, including downregulation of pro-inflammatory and upregulation of anti-inflammatory cytokine gene expression, and increased concentration of total SCFAs including butyrate, acetate, and propionate. Wheel running further led to a shift in bacterial community structure corresponding to higher abundances of Gram-negative bacteria. As these physiological changes have been associated with protection against chronic inflammatory diseases in humans such as IBD, we conclude that PA prior to disease onset can prime the intestines, enhancing their tolerance to inflammation. These benefits however are lost when PA is imposed

in the absence of a healthy mucosal layer. Overall, the findings here suggest that PA in healthy individuals may be an important preventative medicine against intestinal diseases such as IBD.

Primer Name	Primer Sequence	T _m (°C)	Length (bp)	Efficiency
18S-F	CGGCTACCACATCCAAGGAA	48.9	20	1.13
18S-R	GCTGGAATTACCGCGGCT	45.2	18	
IFN γ -F	TCAAGTGGCATAGATGTGGAAGAA	54.5	24	1.14
IFN γ -R	TGGCTCTGCAGGATTTTCATG	50.5	21	
TNF α -F	CATCTTCTCAAAATTCGAGTGACAA	55.4	25	1.19
TNF α -R	TGGGAGTAGAACAAGGTACAACCC	54.3	24	
TGF- β -F	GACCGCAACAACGCCATCTA	48.9	20	1.05
TGF- β -R	AGCCCTGTATTCCGTCTCCTT	50.5	21	
IL-10-F	AGGGCCCTTTGCTATGGTGT	48.9	20	0.97
IL-10-R	TGGCCACAGTTTTCAGGGAT	48.9	20	
CLDN10-F	GGCGTTGGATGGTTACATCC	48.9	20	1.27
CLDN10-R	AATCCCGGCCAAGCAAGCGA	48.9	20	
CXCL9-F	AGTGTGGAGTTCGAGGAAC	47.1	19	1.01
CXCL9-R	GAAATCATTGCTACACTGAAGAAC	54.4	24	
Tbp-F	ACCGTGAATCTTGGCTGTAAAC	52.0	22	0.89
Tbp-R	GCAGCAAATCGCTTGGGATTA	50.5	21	
RELM- β -F	ATGGGTGTCACTGGATGTGCTT	51.9	22	0.92
RELM- β -R	AGCACTGGCAGTGGCAAGTA	48.9	20	
RegIII- γ -F	CCCGTATAACCATCACCATCAT	51.9	22	0.94
RegIII- γ -R	GGCATCTTTCTTGGCAACTTC	50.5	21	

Supplementary Material 6. List of RT-qPCR primers used.

T_m refers to the primer melting temperature. Length (bp) refers to primer length in base pairs. Primer names ending with '-F' or '-R' refer to forward and reverse primers, respectively.

Availability of data:

All data and codes used for all aspects of this manuscript, including all metadata, histology figures, and raw sequence files are currently available publicly at <https://osf.io/9awgd/>

All used software packages, versions, and parameters from the QIIME 2 software are available under the 'provenance' tab of the accompanying qiime2 zip artifact (.qza) files. These files can be viewed locally or on a web browser at <https://view.qiime2.org/>.

Acknowledgements:

Author contributions:

Conceptualization: ME, DLG; **Data curation:** ME; **Formal Analysis:** ME, JP; **Funding acquisition:** DLG; **Investigation:** ME, DWM, CQ, AG, SKG, JAB; **Methodology:** ME, DLG; **Project administration:** ME, DLG; **Resources:** DLG; **Software:** ME, JP; **Supervision:** DLG; **Validation:** ME, JP; **Visualization:** ME; **Writing – original draft:** ME; **Writing – review & editing:** ME, DWM, CQ, JP, JB, SG, DLG

Funding Information:

This project was funded by Crohns & Colitis Canada (CCC) and Natural Sciences and Engineering Research Council (NSERC) awarded to DG.

ME was funded by an NSERC PGSD, CQ: CIHR CGSD, JP: NSERC discovery, JB: NSERC USRA

References:

1. Sheehan D, Moran C, Shanahan F. 2015. The microbiota in inflammatory bowel disease. *J Gastroenterol* 50:495–507.
2. Harris KG, Chang EB. 2018. The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. *Clin Sci* 132:2013–2028.
3. Shaw SY, Blanchard JF, Bernstein CN. 2011. Association Between the Use of Antibiotics and New Diagnoses of Crohn's Disease and Ulcerative Colitis. *Am J Gastroenterol* 106:2133–2142.
4. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect Immun* 66:5224–31.
5. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H, Alipour V, Almadi MAH, Almasi-Hashiani A, Anushiravani A, Arabloo J, Atique S, Awasthi A, Badawi A, Baig AAA, Bhala N, Bijani A, Biondi A, Borzi AM, Burke KE, Carvalho F, Daryani A, Dubey M, Eftekhari A, Fernandes E, Fernandes JC, Fischer F, Haj-Mirzaian A, Haj-Mirzaian A, Hasanzadeh A, Hashemian M, Hay SI, Hoang CL, Househ M, Ilesanmi OS, Balalami NJ, James SL, Kengne AP, Malekzadeh

- MM, Merat S, Meretoja TJ, Mestrovic T, Mirrakhimov EM, Mirzaei H, Mohammad KA, Mokdad AH, Monasta L, Negoï I, Nguyen TH, Nguyen CT, Pourshams A, Poustchi H, Rabiee M, Rabiee N, Ramezanzadeh K, Rawaf DL, Rawaf S, Rezaei N, Robinson SR, Ronfani L, Saxena S, Sepehrimanesh M, Shaikh MA, Sharafi Z, Sharif M, Siabani S, Sima AR, Singh JA, Soheili A, Sotoudehmanesh R, Suleria HAR, Tesfay BE, Tran B, Tsoi D, Vacante M, Wondmieneh AB, Zarghi A, Zhang ZJ, Dirac M, Malekzadeh R, Naghavi M. 2020. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol* 5:17–30.
6. Booth FW, Roberts CK, Laye MJ. 2012. Lack of exercise is a major cause of chronic diseases. *Compr Physiol* 2:1143–1211.
 7. Bilski J, Mazur-Bialy A, Brzozowski B, Magierowski M, Zahradnik-Bilska J, Wójcik D, Magierowska K, Kwiecien S, Mach T, Brzozowski T. 2016. Can exercise affect the course of inflammatory bowel disease? Experimental and clinical evidence. *Pharmacol Rep* 68:827–36.
 8. Bilski J, Mazur-Bialy AI, Brzozowski B, Magierowski M, Jasnos K, Krzysiek-Maczka G, Urbanczyk K, Ptak-Belowska A, Zwolinska-Wcislo M, Mach T, Brzozowski T. 2015. Moderate exercise training attenuates the severity of experimental rodent colitis: The importance of crosstalk between adipose tissue and skeletal muscles. *Mediators Inflamm* 2015.
 9. Cook MD, Martin S a, Williams C, Whitlock K, Wallig M a, Pence BD, Woods J a. 2013. Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis. *Brain Behav Immun*.
 10. Saxena A, Fletcher E, Larsen B, Baliga MS, Durstine JL, Fayad R. 2012. Effect of exercise on chemically-induced colitis in adiponectin deficient mice. *J Inflamm (Lond)* 9:30.
 11. Szalai Z, Szász A, Nagy I, Puskás LG, Kupai K, Király A, Berkó AM, Pósa A, Strifler G, Baráth Z, Nagy LI, Szabó R, Pávó I, Murlasits Z, Gyöngyösi M, Varga C. 2014. Anti-Inflammatory Effect of Recreational Exercise in TNBS-Induced Colitis in Rats: Role of NOS/HO/MPO System. *Oxid Med Cell Longev* 2014:925981.
 12. Faderl M, Noti M, Corazza N, Mueller C. 2015. Keeping bugs in check: The mucus layer as a critical component in maintaining intestinal homeostasis. *IUBMB Life* 67:275–285.
 13. Fyderek K, Strus M, Kowalska-Duplaga K, Gosiewski T, Wedrychowicz A, Jedynek-Wasowicz U, Śladek M, Pieczarkowski S, Adamski P, Kochan P, Heczko PB. 2009. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. *World J Gastroenterol* 15:5287–94.
 14. Van der Sluis M, De Koning BAE, De Bruijn ACJM, Velcich A, Meijerink JPP, Van Goudoever JB, Büller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AWC. 2006. Muc2-Deficient Mice Spontaneously Develop Colitis, Indicating That MUC2 Is Critical for Colonic Protection. *Gastroenterology* 131:117–129.
 15. Morampudi V, Dalwadi U, Bhinder G, Sham HP, Gill SK, Chan J, Bergstrom KSB, Huang T, Ma C, Jacobson K, Gibson DL, Vallance BA. 2016. The goblet cell-derived mediator RELM-β drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. *Mucosal Immunol*.
 16. Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, Ahmadi-Vand Z, Marsden KR, Gibson DL. 2016. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. *Microbiome*.
 17. Kim YJ, Kim HJ, Lee WJ, Seong JK. 2020. A comparison of the metabolic effects of treadmill and wheel running exercise in mouse model. *Lab Anim Res* 36.
 18. Moraska A, Deak T, Spencer RL, Roth D, Fleshner M. 2000. Treadmill running produces both positive and negative physiological adaptations in Sprague-Dawley rats. *Am J*

- Physiol - Regul Integr Comp Physiol 279.
19. Allen JM, Berg Miller ME, Pence BD, Whitlock K, Nehra V, Gaskins HR, White BA, Fryer JD, Woods JA. 2015. Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6J mice. *J Appl Physiol* 118:1059–66.
 20. Mazur-Bial AI, Bilski J, Wojcik D, Brzozowski B, Surmiak M, Hubalewska-Mazgaj M, Chmura A, Magierowski M, Magierowska K, Mach T, Brzozowski T. 2017. Beneficial effect of voluntary exercise on experimental colitis in mice fed a High-Fat diet: The role of irisin, adiponectin and proinflammatory biomarkers. *Nutrients* 9.
 21. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9:671–675.
 22. Bergstrom KSB, Kisson-Singh V, Gibson DL, Ma C, Montero M, Sham HP, Ryz N, Huang T, Velcich A, Finlay BB, Chadee K, Vallance BA. 2010. Muc2 Protects against Lethal Infectious Colitis by Disassociating Pathogenic and Commensal Bacteria from the Colonic Mucosa. *PLoS Pathog* 6:e1000902.
 23. Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De los Reyes-Gavilán CG, Salazar N. 2016. Intestinal short chain fatty acids and their link with diet and human health. *Front Microbiol. Frontiers Media S.A.*
 24. Leonel AJ, Alvarez-Leite JI. 2012. Butyrate: Implications for intestinal function. *Curr Opin Clin Nutr Metab Care. Curr Opin Clin Nutr Metab Care.*
 25. Brown K, Godovannyi A, Ma C, Zhang Y, Ahmadi-Vand Z, Dai C, Gorzelak MA, Chan Y, Chan JM, Lochner A, Dutz JP, Vallance BA, Gibson DL. 2016. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. *ISME J* 10:321–332.
 26. Mailing LJ, Allen JM, Buford TW, Fields CJ, Woods JA. 2019. Exercise and the Gut Microbiome: A Review of the Evidence, Potential Mechanisms, and Implications for Human Health. *Exerc Sport Sci Rev* 47:75–85.
 27. Kang SS, Jeraldo PR, Kurti A, Miller MEB, Cook MD, Whitlock K, Goldenfeld N, Woods JA, White BA, Chia N, Fryer JD. 2014. Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. *Mol Neurodegener* 9:36.
 28. Allen JM, Mailing LJ, Cohrs J, Salmonson C, Fryer JD, Nehra V, Hale VL, Kashyap P, White BA, Woods JA. 2017. Exercise training-induced modification of the gut microbiota persists after microbiota colonization and attenuates the response to chemically-induced colitis in gnotobiotic mice. *Gut Microbes* 0976:1–16.
 29. Lamoureux E V, Grandy SA, Langille MGI. 2017. Moderate Exercise Has Limited but Distinguishable Effects on the Mouse Microbiome. *mSystems* 2:1–14.
 30. Allen JM, Mailing LJ, Niemi GM, Moore R, Cook MD, White BA, Holscher HD, Woods JA. 2018. Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans. *Med Sci Sports Exerc* 50:747–757.
 31. R Development Core Team R. 2011. R: A Language and Environment for Statistical Computing. *R Foundation for Statistical Computing.*
 32. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang K Bin, Keefe CR, Keim P, Kelley ST, Knights D, Koester I, Kosciolk T, Kreps J, Langille MGI, Lee J, Ley R, Liu YX, Lofffield E, Lozupone C, Maher M, Marotz C, Martin BD, McDonald D, McIver LJ, Melnik A V., Metcalf JL, Morgan SC, Morton JT, Naimey AT, Navas-Molina JA, Nothias LF, Orchanian SB, Pearson T, Peoples

- SL, Petras D, Preuss ML, Pruesse E, Rasmussen LB, Rivers A, Robeson MS, Rosenthal P, Segata N, Shaffer M, Shiffer A, Sinha R, Song SJ, Spear JR, Swafford AD, Thompson LR, Torres PJ, Trinh P, Tripathi A, Turnbaugh PJ, Ul-Hasan S, van der Hooft JJJ, Vargas F, Vázquez-Baeza Y, Vogtmann E, von Hippel M, Walters W, Wan Y, Wang M, Warren J, Weber KC, Williamson CHD, Willis AD, Xu ZZ, Zaneveld JR, Zhang Y, Zhu Q, Knight R, Caporaso JG. 2019. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol*. Nature Publishing Group.
33. Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal* 17:10.
 34. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat Methods* 13:581–583.
 35. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL, Knight R, Hugenholtz P. 2012. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *ISME J* 6:610–618.
 36. Rognes T, Flouri T, Nichols B, Quince C, Mahé F. 2016. VSEARCH: a versatile open source tool for metagenomics. *PeerJ* 4:e2584.
 37. Janssen S, McDonald D, Gonzalez A, Navas-Molina JA, Jiang L, Xu ZZ, Winker K, Kado DM, Orwoll E, Manary M, Mirarab S, Knight R. 2018. Phylogenetic Placement of Exact Amplicon Sequences Improves Associations with Clinical Information. *mSystems* 3.
 38. Yarza P, Richter M, Peplies J, Euzéby J, Amann R, Schleifer KH, Ludwig W, Glöckner FO, Rosselló-Móra R. 2008. The All-Species Living Tree project: A 16S rRNA-based phylogenetic tree of all sequenced type strains. *Syst Appl Microbiol* 31:241–250.
 39. Murali A, Bhargava A, Wright ES. 2018. IDTAXA: A novel approach for accurate taxonomic classification of microbiome sequences. *Microbiome* 6.
 40. Heintz-Buschart A, Wilmes P. 2018. Human Gut Microbiome: Function Matters. *Trends Microbiol*. Elsevier Ltd.
 41. Ward T, Larson J, Meulemans J, Hillmann B, Lynch J, Sidiropoulos D, Spear J, Caporaso G, Blekhman R, Knight R, Fink R, Knights D. 2017. BugBase Predicts Organism Level Microbiome Phenotypes. *bioRxiv* 133462.
 42. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. 2013. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 31:814–821.
 43. Wang Y, Naumann U, Wright ST, Warton DI. 2012. mvabund - an R package for model-based analysis of multivariate abundance data. *Methods Ecol Evol* 3:471–474.
 44. Martino C, Morton JT, Marotz CA, Thompson LR, Tripathi A, Knight R, Zengler K. 2019. A Novel Sparse Compositional Technique Reveals Microbial Perturbations. *mSystems* 4.
 45. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. 2013. EMPERor: a tool for visualizing high-throughput microbial community data. *Gigascience* 2:16.
 46. Anderson MJ. 2001. A new method for non-parametric multivariate analysis of variance. *Austral Ecol* 26:32–46.
 47. Willis AD, Martin BD. 2018. DivNet: Estimating diversity in networked communities. *bioRxiv* 305045.
 48. Martin BD, Witten D, Willis AD. 2020. Modeling microbial abundances and dysbiosis with beta-binomial regression. *Ann Appl Stat* 14:94–115.
 49. Goh WW Bin, Wang W, Wong L. 2017. Why Batch Effects Matter in Omics Data, and How to Avoid Them. *Trends Biotechnol* 35:498–507.
 50. van der Sluis M, Bouma J, Vincent A, Velcich A, Carraway KL, Büller HA, Einerhand AWC, van Goudoever JB, Van Seuningen I, Renes IB. 2008. Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation:

- mucin 2-interleukin 10-deficient mice. *Lab Investig* 88:634–642.
51. Singh U, Venkataraman C, Singh R, Lillard Jr. J. 2007. CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication. *Endocrine, Metab Immune Disord Targets* 7:111–123.
 52. Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP. 2020. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. *Gut Pathog* 12:1.
 53. Zhang Q, Wu Y, Wang J, Wu G, Long W, Xue Z, Wang L, Zhang X, Pang X, Zhao Y, Zhao L, Zhang C. 2016. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium. *Sci Rep* 6.
 54. Lee KW, Kim M, Lee CH. 2018. Treatment of dextran sulfate sodium-induced colitis with mucosa-associated lymphoid tissue lymphoma translocation 1 inhibitor MI-2 is associated with restoration of gut immune function and the microbiota. *Infect Immun* 86.
 55. Lagkouvardos I, Lesker TR, Hitch TCA, Gálvez EJC, Smit N, Neuhaus K, Wang J, Baines JF, Abt B, Stecher B, Overmann J, Strowig T, Clavel T. 2019. Sequence and cultivation study of Muribaculaceae reveals novel species, host preference, and functional potential of this yet undescribed family. *Microbiome* 7.
 56. Ouwkerk JP, Aalvink S, Belzer C, de Vos WM. 2016. *Akkermansia glycaniphila* sp. nov., an anaerobic mucin-degrading bacterium isolated from reticulated python faeces. *Int J Syst Evol Microbiol* 66:4614–4620.
 57. Lopez-Siles M, Enrich-Capó N, Aldeguer X, Sabat-Mir M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. 2018. Alterations in the Abundance and Co-occurrence of *Akkermansia muciniphila* and *Faecalibacterium prausnitzii* in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. *Front Cell Infect Microbiol* 8.
 58. Naito Y, Uchiyama K, Takagi T. 2018. A next-generation beneficial microbe: *Akkermansia muciniphila*. *J Clin Biochem Nutr* 63:33–35.
 59. Reunanen J, Kainulainen V, Huuskonen L, Ottman N, Belzer C, Huhtinen H, de Vos WM, Satokari R. 2015. *Akkermansia muciniphila* Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer. *Appl Environ Microbiol* 81:3655–62.
 60. Rajilić-Stojanović M, Shanahan F, Guarner F, de Vos WM. 2013. Phylogenetic Analysis of Dysbiosis in Ulcerative Colitis During Remission. *Inflamm Bowel Dis* 19:481–488.
 61. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, Flint HJ, Louis P. 2014. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. *ISME J* 8:1323–1335.
 62. Cook MD, Martin S a, Williams C, Whitlock K, Wallig M a, Pence BD, Woods J a. 2013. Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis. *Brain Behav Immun* 33:46–56.
 63. Packer N, Hoffman-Goetz L, Ward G. 2010. Does physical activity affect quality of life, disease symptoms and immune measures in patients with inflammatory bowel disease? A systematic review. *J Sports Med Phys Fitness* 50:1–18.
 64. Nobile S, Grand RJ, Pappa HM. 2018. Risk factors for low bone mineral density in pediatric inflammatory bowel disease: The positive role of physical activity. *Eur J Gastroenterol Hepatol* 30:471–476.
 65. Robinson RJ, Krzywicki T, Almond L, Al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF. 1998. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: A randomized controlled trial. *Gastroenterology* 115:36–41.
 66. Strober W, Fuss IJ. 2011. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 140:1756–1767.
 67. Popa C, Netea MG, van Riel PLCM, van der Meer JWM, Stalenhoef AFH. 2007. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and

- cardiovascular risk. *J Lipid Res* 48:751–62.
68. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, Tsuji N, Sakamaki S, Niitsu Y, Watanabe N. 2001. Tumor Necrosis Factor- α in Serum of Patients with Inflammatory Bowel Disease as Measured by a Highly Sensitive Immuno-PCR. *Clin Chem* 47.
 69. Mueller C. 2002. Tumour necrosis factor in mouse models of chronic intestinal inflammation. *Immunology* 105:1–8.
 70. Fais S, Capobianchi MR, Silvestri M, Mercuri F, Pallone F, Dianzani F. 1994. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. *J Interferon Res* 14:235–8.
 71. Sasaki T, Hiwatashi N, Yamazaki H, Noguchi M, Toyota T. 1992. The role of interferon gamma in the pathogenesis of Crohn's disease. *Gastroenterol Jpn* 27:29–36.
 72. Verma R, Verma N, Paul J. Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level. *Eur Cytokine Netw* 24:130–8.
 73. Obermeier F, Kojouharoff G, Hans W, Schölmerich J, Gross V, Falk W. 1999. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. *Clin Exp Immunol* 116:238–45.
 74. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O. 2006. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. *Clin Exp Immunol* 146:330–8.
 75. Abraham C, Dulai PS, Vermeire S, Sandborn WJ. 2017. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. *Gastroenterology* 152:374-388.e4.
 76. Ihara S, Hirata Y, Koike K. 2017. TGF- β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. *J Gastroenterol* 52:777–787.
 77. Babyatsky MW, Rossiter G, Podolsky DK. 1996. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. *Gastroenterology* 110:975–84.
 78. McCabe RP, Secrist H, Botney M, Egan M, Peters MG. 1993. Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. *Clin Immunol Immunopathol* 66:52–8.
 79. Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 Therapy--Review of a New Approach. *Pharmacol Rev* 55:241–269.
 80. Hoffman-Goetz L, Spagnuolo PA, Guan J. 2008. Repeated exercise in mice alters expression of IL-10 and TNF- α in intestinal lymphocytes. *Brain Behav Immun* 22:195–199.
 81. Vilorio M, Lara-Padilla E, Campos-Rodríguez R, Jarillo-Luna A, Reyna-Garfias H, López-Sánchez P, Rivera-Aguilar V, Salas-Casas A, Berral de la Rosa FJ, García-Latorre E. 2011. Effect of moderate exercise on IgA levels and lymphocyte count in mouse intestine. *Immunol Invest* 40:640–56.
 82. Hesse C, Andersson B, Wold AE. 2000. Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while gram-negative bacteria preferentially stimulate IL-10 production. *Infect Immun* 68:3581–6.
 83. Floch MH, Hong-Curtiss J. 2002. Probiotics and Functional Foods in Gastrointestinal Disorders. *Curr Treat Options Gastroenterol* 5:311–321.
 84. Tedelind S, Westberg F, Kjerrulf M, Vidal A. 2007. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. *World J Gastroenterol* 13:2826–32.

85. Venter CS, Vorster HH, Cummings JH. 1990. Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers. *Am J Gastroenterol* 85:549–53.
86. Huda-Faujan N, Abdulmir AS, Fatimah AB, Anas OM, Shuhaimi M, Yazid AM, Loong YY. 2010. The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. *Open Biochem J* 4:53–8.
87. Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. 2000. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. *Gut* 47:397–403.
88. Plöger S, Stumpff F, Penner GB, Schulzke J-D, Gäbel G, Martens H, Shen Z, Günzel D, Aschenbach JR. 2012. Microbial butyrate and its role for barrier function in the gastrointestinal tract. *Ann N Y Acad Sci* 1258:52–59.
89. Matsumoto M, Inoue R, Tsukahara T, Ushida K, Chiji H, Matsubara N, Hara H. 2008. Voluntary running exercise alters microbiota composition and increases n-butyrate concentration in the rat cecum. *Biosci Biotechnol Biochem* 72:572–6.
90. Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes E, Shanahan F, Cotter PD, O'Sullivan O. 2018. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. *Gut* 67:625–633.
91. van Hoek MJA, Merks RMH. 2012. Redox balance is key to explaining full vs. partial switching to low-yield metabolism. *BMC Syst Biol* 6:22.
92. Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O'Reilly M, Jeffery IB, Wood-Martin R, Kerins DM, Quigley E, Ross RP, O'Toole PW, Molloy MG, Falvey E, Shanahan F, Cotter PD. 2014. Exercise and associated dietary extremes impact on gut microbial diversity. *Gut* 1–8.
93. Denou E, Marcinko K, Surette MG, Steinberg GR, Schertzer JD. 2016. High-intensity exercise training increases the diversity and metabolic capacity of the mouse distal gut microbiota during diet-induced obesity. *Am J Physiol Endocrinol Metab* 310:E982-93.
94. Liu Z, Liu HY, Zhou H, Zhan Q, Lai W, Zeng Q, Ren H, Xu D. 2017. Moderate-intensity exercise affects gut microbiome composition and influences cardiac function in myocardial infarction mice. *Front Microbiol* 8:1–11.
95. Lai Z-L, Tseng C-H, Ho HJ, Cheung CKY, Lin J-Y, Chen Y-J, Cheng F-C, Hsu Y-C, Lin J-T, El-Omar EM, Wu C-Y. 2018. Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice. *Sci Rep* 8:15625.
96. Brandt N, Kotowska D, Kristensen CM, Olesen J, Lützhøft DO, Halling JF, Hansen M, Al-Soud WA, Hansen L, Kiilerich P, Pilegaard H. 2018. The impact of exercise training and resveratrol supplementation on gut microbiota composition in high-fat diet fed mice. *Physiol Rep* 6:1–11.
97. Welly RJ, Liu T-W, Zidon TM, Rowles JL, Park Y-M, Smith TN, Swanson KS, Padilla J, Vieira-Potter VJ. 2016. Comparison of Diet versus Exercise on Metabolic Function and Gut Microbiota in Obese Rats. *Med Sci Sports Exerc* 48:1688–98.
98. Bressa C, Bailén-Andrino M, Pérez-Santiago J, González-Soltero R, Pérez M, Montalvo-Lominchar MG, Maté-Muñoz JL, Domínguez R, Moreno D, Larrosa M. 2017. Differences in gut microbiota profile between women with active lifestyle and sedentary women. *PLoS One* 12:e0171352.
99. Wexler AG, Goodman AL. 2017. An insider's perspective: Bacteroides as a window into the microbiome. *Nat Microbiol*. Nature Publishing Group.
100. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, Scott KP, Flint HJ, Louis P. 2014. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. *ISME J* 8:1323–35.
101. Lee YK, Mehrabian P, Boyajian S, Wu W-L, Selicha J, Vonderfecht S, Mazmanian SK.

2018. The Protective Role of *Bacteroides fragilis* in a Murine Model of Colitis-Associated Colorectal Cancer . *mSphere* 3.
102. Chang YC, Ching YH, Chiu CC, Liu JY, Hung SW, Huang WC, Huang Y Te, Chuang HL. 2017. TLR2 and interleukin-10 are involved in *Bacteroides fragilis*-mediated prevention of DSS-induced colitis in gnotobiotic mice. *PLoS One* 12.
103. Brito IL, Yilmaz S, Huang K, Xu L, Jupiter SD, Jenkins AP, Naisilisili W, Tamminen M, Smillie CS, Wortman JR, Birren BW, Xavier RJ, Blainey PC, Singh AK, Gevers D, Alm EJ. 2016. Mobile genes in the human microbiome are structured from global to individual scales. *Nature* 535:435–439.